For Healthcare Professionals

NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC

clipboard-pencil

About the study

This is a multicenter, open-label, single-arm Phase II study to evaluate anti-tumor efficacy and safety of NT-I7 in combination with atezolizumab in subjects with PD-L1-expressing (TPS ≥ 1%), metastatic (Stage IV) or locally advanced squamous or non-squamous NSCLC who have not received prior systemic therapy in the metastatic or locally advanced setting. Eligible subjects must have measurable disease according to RECIST 1.1. This Phase II study will enroll up to 83 subjects.
user-3

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

INCLUSION CRITERIA

  1. Have histologically or cytologically confirmed metastatic or locally advanced NSCLC, and have not received prior systemic therapy. Subjects with locally advanced disease must have Stage III NSCLC and are not candidates for surgical resection or definitive chemoradiation
  2. Tumor PD-L1 expression (TPS≥1%) as determined by PD-L1 22C3 immunohistochemistry local or central assay.
  3. Have measurable disease
  4. Agree to provide screening biopsy (or archival tissue) at screening to assess PD-L1
  5. ECOG 0-1
  6. Adequate hematologic and end organ function

EXCLUSION CRITERIA

  1. Prior systemic anti-cancer therapy
  2. NSCLC with EGFR, or ALK, or BRAF or ROS or RED or other genomic tumor aberrations which have available therapy
  3. Prior radiotherapy within 2 weeks of start of study treatment
  4. Known active CNS metastasis or carcinomatous meningitis
  5. Severe reactions to mAbs or IV immunoglobulin preparations
  6. Autoimmune disease history in past two years
pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply


Contact the study center to learn if this study is a good match for you.
Phone iconCall 301-337-2283Email iconEmail Study Center

Study’s details


Contition

Carcinoma, Non-Small-Cell Lung,Non Small Cell Lung Cancer,Non-Small Cell Lung Cancer,Non-Small Cell Lung Carcinoma,Nonsmall Cell Lung Cancer

Age

18+

Phase

Phase 2

Participants needed

83

Est. Completion Date

Jun 2024

Treatment type

Interventional


Sponsor

NeoImmuneTech

ClinicalTrials.gov identifier

NCT04984811

Study number

NIT-119

Understanding Clinical Trials


Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?
Vector

Interested?

Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.